Mostrar el registro sencillo del ítem

dc.contributor.authorKauer-Sant'Anna, Márciapt_BR
dc.contributor.authorKapczinski, Flávio Pereirapt_BR
dc.contributor.authorAndreazza, Ana Cristinapt_BR
dc.contributor.authorBond, David J.pt_BR
dc.contributor.authorLam, Raymond W.pt_BR
dc.contributor.authorYoung, L. Trevorpt_BR
dc.contributor.authorYatham, Lakshmi N.pt_BR
dc.date.accessioned2016-09-27T02:14:35Zpt_BR
dc.date.issued2009pt_BR
dc.identifier.issn1461-1457pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/148544pt_BR
dc.description.abstractBipolar I disorder (BD) has a poorer longer-term outcome than previously thought, with persistent cognitive impairment and functional decline. The neurobiological underpinnings that might underlie these changes remain unknown. Changes in brain-derived neurotrophic factor (BDNF) levels and cytokines are potential candidates. The aim of this study was to examine both cytokine and BDNF levels and their relationship in BD patients in the early and late stages of the disorder. We measured serum BDNF, TNF-a, IL-6 and IL-10 levels in a total of 60 patients with BD I and we compared those in early stages of illness with those in late stages of illness and also compared both groups with 60 matched healthy controls. BDNF was decreased only in those patients in the late stage of bipolar disorder. Moreover, BDNF levels were negatively correlated with length of illness. In contrast, all interleukins and TNF-a were increased in the early stages of BD, compared to controls. While TNF-a and IL-6 continued to be significantly higher than controls at late stages of BD, IL-10 did not. When levels were compared between patients at early and late stages of illness, there was a significant decrease in BDNF and IL-6 in the later stage of BD compared to the early stage. Inversely, TNF-a showed a significant increase at the later stage. Failure of inflammatory defences in the late stage of the disorder may account for reduction in BDNF and continued elevations in cytokines; thus these may have the potential to serve as markers of illness progression in BD.en
dc.format.mimetypeapplication/pdf
dc.language.isoengpt_BR
dc.relation.ispartofInternational journal of neuropsychopharmacology. Cambridge. Vol. 12, no. 4 (2009), p. 447-458pt_BR
dc.rightsOpen Accessen
dc.subjectBipolar disorderen
dc.subjectTranstorno bipolarpt_BR
dc.subjectBDNFen
dc.subjectFator neurotrófico derivado do encéfalopt_BR
dc.subjectCitocinaspt_BR
dc.subjectCytokinesen
dc.subjectFirst episodeen
dc.subjectInterleucinaspt_BR
dc.subjectFator de necrose tumoral alfapt_BR
dc.subjectInterleukinsen
dc.subjectPsicopatologiapt_BR
dc.subjectTNF-aen
dc.subjectTranstornos mentaispt_BR
dc.titleBrain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorderpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000722686pt_BR
dc.type.originEstrangeiropt_BR


Ficheros en el ítem

Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem